Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2025-12-27 @ 11:29 PM
Study NCT ID:
NCT05394233
Status:
UNKNOWN
Last Update Posted:
2022-05-27
First Post:
2022-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sponsor:
Sichuan Cancer Hospital and Research Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-24
First Submit QC Date:
None
Study First Post Date:
2022-05-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-24
Last Update Post Date:
2022-05-27
Last Update Post Date Type:
ACTUAL